ILUMYA DOSING & ADMINISTRATION

ENHANCE COMPLIANCE AND SEE YOUR PATIENTS' PROGRESS AT EVERY VISIT1

THE ONLY SINGLE-INJECTION IL-23 INHIBITOR WITH QUARTERLY DOSING2-4

ILUMYA 52-Week Dosing Graph
Dosing Body Icon

1 DOSE = ONE 100 mg INJECTION

  • The 100 mg dose of ILUMYA™ is recommended for all patients, regardless of weight.2

TREATMENT OPTIONS FOR
MODERATE-TO-SEVERE PLAQUE PSORIASIS*

ILUMYA_1_YRCreated with Sketch.2INJECTIONS2ILUMYA™(tildrakizumab)Following 2 starter doses at Weeks 0 and 4IL-23 INHIBITORONE 100 mg injection per Q12W maintenance dose
  • SKYRIZI_1_YRCreated with Sketch.4INJECTIONS3Skyrizi™(risankizumab) Following 2 starter doses at Weeks 0 and 4IL-23 INHIBITORTWO 75 mg injections per Q12W maintenance dose
  • TREMFYA_1_YRCreated with Sketch.3INJECTIONS4Tremfya®(guselkumab)Following 2 starter doses at Weeks 0 and 4IL-23 INHIBITORONE 100 mg injection per Q8W maintenance dose
  • STELARA_1_YRCreated with Sketch.ONE 45 mg or 90 mg injection per Q12W maintenance dose2INJECTIONS5Stelara®(ustekinumab)Following 2 starter doses at Weeks 0 and 4††IL-12/23 INHIBITOR
  • OTEZLA_1_YRCreated with Sketch.167TABLETS6Otezla®(apremilast)Following initial titration of one 10 mg dose on Day 1, two 10 mg doses on Day 2, two doses [one 10 mg and one 20 mg] on Day 3, two 20 mg doses on Day 4, and two doses [one 20 mg and one 30 mg] on Day 5PDE4 INHIBITORONE 30 mg tablet per BID maintenance dose
  • COSENTYX_1_YRCreated with Sketch.14INJECTIONS7Cosentyx®(secukinumab)Following 5 starter doses at Weeks 0, 1, 2, 3, 4TWO 150 mg injections per Q4W maintenance dose‡IL-17 INHIBITOR
  • TALTZ_1_YRCreated with Sketch.8INJECTIONS8Taltz®(ixekizumab)Following starter doses of 160 mg at Week 0, then 80 mg at Weeks 2, 4, 6, 8, 10, and 12IL-17 INHIBITORONE 80 mg injection per Q4W maintenance dose
  • ENBREL_1_YRCreated with Sketch.24INJECTIONS9Enbrel®(etanercept) Following twice weekly dosing for the first 3 months§TNF INHIBITORONE 50 mg injection per QW maintenance dose
  • HUMIRA_1_YRCreated with Sketch.7INJECTIONS10Humira®(adalimumab)Following one 80 mg starter doseTNF INHIBITORONE 40 mg injection per QOW maintenance dose
ILUMYA_1_YRCreated with Sketch.IL-23 INHIBITORILUMYA™(tildrakizumab)6INJECTIONS2Following 2 starter doses at Weeks 0 and 4ONE 100 mg injection per Q12W maintenance dose
  • SKYRIZI_1_YRCreated with Sketch.Skyrizi™(risankizumab)12INJECTIONS3 Following 2 starter doses at Weeks 0 and 4TWO 75 mg injections per Q12W maintenance doseIL-23 INHIBITOR
  • TREMFYA_1_YRCreated with Sketch.IL-23 INHIBITORTremfya®(guselkumab)8INJECTIONS4Following 2 starter doses at Weeks 0 and 4ONE 100 mg injection per Q8W maintenance dose
  • STELARA_1_YRCreated with Sketch.IL-12/23 INHIBITORStelara®(ustekinumab)ONE 45 mg or 90 mg injection per Q12W maintenance dose6INJECTIONS5Following 2 starter doses at Weeks 0 and 4††
  • OTEZLA_1_YRCreated with Sketch.PDE4 INHIBITOROtezla®(apremilast)729TABLETS6Following initial titration of one 10 mg dose on Day 1, two 10 mg doses on Day 2, two doses [one 10 mg and one 20 mg] on Day 3, two 20 mg doses on Day 4, and two doses [one 20 mg and one 30 mg] on Day 5ONE 30 mg tablet per BID maintenance dose
  • COSENTYX_1_YRCreated with Sketch.IL-17 INHIBITORCosentyx®(secukinumab)34INJECTIONS7Following 5 starter doses at Weeks 0, 1, 2, 3, 4TWO 150 mg injections per Q4W maintenance dose‡
  • TALTZ_1_YRCreated with Sketch.IL-17 INHIBITORTaltz®(ixekizumab)18INJECTIONS8Following starter doses of 160 mg at Week 0, then 80 mg at Weeks 2, 4, 6, 8, 10, and 12ONE 80 mg injection per Q4W maintenance dose
  • ENBREL_1_YRCreated with Sketch.TNF INHIBITOREnbrel®(etanercept)64INJECTIONS9 Following twice weekly dosing for the first 3 months§ONE 50 mg injection per QW maintenance dose
  • HUMIRA_1_YRCreated with Sketch.TNF INHIBITORHumira®(adalimumab)27INJECTIONS10Following one 80 mg starter doseONE 40 mg injection per QOW maintenance dose
ILUMYA_1_YRCreated with Sketch.ILUMYA™(tildrakizumab)10INJECTIONS2Following 2 starter doses at Weeks 0 and 4ONE 100 mg injection per Q12W maintenance doseIL-23 INHIBITOR
  • SKYRIZI_1_YRCreated with Sketch.Skyrizi™(risankizumab)20INJECTIONS3 Following 2 starter doses at Weeks 0 and 4TWO 75 mg injections per Q12W maintenance doseIL-23 INHIBITOR
  • TREMFYA_1_YRCreated with Sketch.Tremfya®(guselkumab)14INJECTIONS4Following 2 starter doses at Weeks 0 and 4ONE 100 mg injection per Q8W maintenance doseIL-23 INHIBITOR
  • STELARA_1_YRCreated with Sketch.Stelara®(ustekinumab)ONE 45 mg or 90 mg injection per Q12W maintenance dose10INJECTIONS5Following 2 starter doses at Weeks 0 and 4††IL-12/23 INHIBITOR
  • OTEZLA_1_YRCreated with Sketch.PDE4 INHIBITOROtezla®(apremilast)1459TABLETS6Following initial titration of one 10 mg dose on Day 1, two 10 mg doses on Day 2, two doses [one 10 mg and one 20 mg] on Day 3, two 20 mg doses on Day 4, and two doses [one 20 mg and one 30 mg] on Day 5ONE 30 mg tablet per BID maintenance dose
  • COSENTYX_1_YRCreated with Sketch.Cosentyx®(secukinumab)60INJECTIONS7Following 5 starter doses at Weeks 0, 1, 2, 3, 4TWO 150 mg injections per Q4W maintenance dose‡IL-17 INHIBITOR
  • TALTZ_1_YRCreated with Sketch.Taltz®(ixekizumab)31INJECTIONS8Following starter doses of 160 mg at Week 0, then 80 mg at Weeks 2, 4, 6, 8, 10, and 12ONE 80 mg injection per Q4W maintenance doseIL-17 INHIBITOR
  • ENBREL_1_YRCreated with Sketch.Enbrel®(etanercept)116INJECTIONS9 Following twice weekly dosing for the first 3 months§ONE 50 mg injection per QW maintenance doseTNF INHIBITOR
  • HUMIRA_1_YRCreated with Sketch.Humira®(adalimumab)53INJECTIONS10Following one 80 mg starter doseONE 40 mg injection per QOW maintenance doseTNF INHIBITOR

This graphic is not intended to compare the efficacy or safety of the treatments for moderate-to-severe plaque psoriasis shown here. Additional considerations, aside from the dosing profile, should be taken into account before making a treatment decision. For complete product information, refer to each product’s Prescribing Information.

*Indications and dosage information accessed May 2019. For complete product information, including current indications and dosing, refer to each product’s Prescribing Information.
†Reflects adult dosing. One 45 mg or 90 mg injection per dose, based on weight (≤100 kg or >100 kg, respectively).
‡Dosing based on the recommended 300 mg dose. Some patients may receive a 150 mg dose.
§Reflects adult dosing. Alternative starting doses include 25 mg or 50 mg weekly.

Indicated trademarks are registered trademarks of their respective owners.
Skyrizi™ is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Tremfya® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Stelara® is indicated for the treatment of patients 12 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Otezla® is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

Cosentyx® is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Taltz® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Enbrel® is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Humira® is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Humira® should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Hospital Building IconHospital Building Icon

HEALTHCARE PROFESSIONAL ADMINISTRATION

ILUMYA™ should only be administered by a healthcare professional, so you can ensure compliance and monitor your patient’s progress with every dose.2

ADMINISTERING ILUMYA™2

Administration Step 1: Waiting Clock Icon

1

Let the ILUMYA™ carton sit at room temperature for at least 30 minutes before injecting.

Administration Step 2: Injection Site Body Icon

2

Choose an injection site with clear skin and easy access (such as the abdomen, thigh, or upper arm).

Administration Step 3: Tildrakizumab Syringe Icon

3

Inject the full amount (1 mL), which provides 100 mg of tildrakizumab per syringe.

Administration Step 4: Hazardous Waste Bucket Icon

4

Discard the syringe after use.

Storage Calendar Icon

ROOM TEMPERATURE STABILITY CAN ALLOW FOR STORAGE FLEXIBILITY

ILUMYA™ should be refrigerated. 30 minutes before injecting, let ILUMYA™ sit at room temperature. Once stored at room temperature, do not place back in the refrigerator. However, 30-day room temperature stability means ILUMYA™ can be administered later if your patient misses their appointment.2

ILUMYA™ IN ACTION

See how ILUMYA™ precisely targets the inflammatory pathway2

Watch MOA Video

RESPONSE THAT LASTS

See results through Week 14811

Explore Efficacy

INDICATION AND IMPORTANT SAFETY INFORMATION

ILUMYA™ (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

CONTRAINDICATIONS

ILUMYA™ is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity

Cases of angioedema and urticaria occurred in ILUMYA™-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA™ immediately and initiate appropriate therapy.

Infections

ILUMYA™ may increase the risk of infection. Treatment with ILUMYA™ should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing ILUMYA™ in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA™ to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA™ until the infection resolves.

Pretreatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA™. Do not administer ILUMYA™ to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA™. Consider anti-TB therapy prior to initiation of ILUMYA™ in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA™ should be monitored closely for signs and symptoms of active TB during and after treatment.

Immunizations

Prior to initiating therapy with ILUMYA™, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA™ should not receive live vaccines.

Adverse Reactions

The most common (≥1%) adverse reactions associated with ILUMYA™ treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea.

Please see full Prescribing Information.

 

References: 1. Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367. 2. ILUMYA™ [package insert]. Princeton, NJ: Sun Pharmaceuticals, Inc. 3. Skyrizi™ (risankizumab-rzaa) [package insert]. North Chicago, IL: AbbVie Inc. 4. Tremfya® (guselkumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 5. Stelara®(ustekinumab) [prescribing information]. Horsham, PA: Janssen Biotech, Inc. 6. Otezla® (apremilast) [package insert]. Summit, NJ: Celgene Corporation. 7. Cosentyx® (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. 8. Taltz® (ixekizumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company. 9. Enbrel® (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corporation. 10. Humira® (adalimumab) [prescribing information]. North Chicago, IL: AbbVie Inc. 11. Thaçi D, Iversen L, Pau-Charles I, et al. Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were responders at week 28: pooled analysis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase 3 trials. Paper presented at: 27th Congress of the European Academy of Dermatology and Venereology (EADV); September 12-16, 2018; Paris, France.